Since the beginning of the year a significant amount of research data has been reported on histone deacetylases (HDACs), the cellular enzymes whose functions include turning gene expression off and on. They are considered to be among the most promising targets in drug development for cancer therapy. New HDAC inhibitors are emerging and are actively being tested in the clinic. Read More
Linking a radioactive molecule to an antibody to pinpoint the radiation at the tumor is nothing new; targeted radiotherapy has been around for years. Read More
Despite the availability of advanced molecular technologies and the investment of billions of dollars in research and development every year, biopharmaceutical companies have not yet managed to improve their efficiency rate for bringing novel therapies to the marketplace. Read More
